EA200001041A1 - Антитела к cd23, их производные и их терапевтическое применение - Google Patents

Антитела к cd23, их производные и их терапевтическое применение

Info

Publication number
EA200001041A1
EA200001041A1 EA200001041A EA200001041A EA200001041A1 EA 200001041 A1 EA200001041 A1 EA 200001041A1 EA 200001041 A EA200001041 A EA 200001041A EA 200001041 A EA200001041 A EA 200001041A EA 200001041 A1 EA200001041 A1 EA 200001041A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
derivatives
therapeutic application
fcεrii
bind
Prior art date
Application number
EA200001041A
Other languages
English (en)
Inventor
Жан-Ив Марсель Поль Боннефуа
Скотт Джеймс Кроу
Джонатан Генри Эллис
Николас Тимоти Рапсон
Джин Ширин
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA200001041A1 publication Critical patent/EA200001041A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение относится к антителам, которые связываются с молекулой CD23 типа II (FCεRII), в частности к измененным антителам, включая антитела, которые связываются с молекулой CD23 типа II (FCεRII), отличающимся константой аффинности, равной или превышающей Ka 1x10моль, получению таких антител, фармацевтическим композициям, которые содержат такие антитела, и их применению в терапии, особенно при лечении аутоиммунных и воспалительных заболеваний.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200001041A 1998-05-09 1999-05-07 Антитела к cd23, их производные и их терапевтическое применение EA200001041A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody
PCT/GB1999/001434 WO1999058679A1 (en) 1998-05-09 1999-05-07 Antibodies to cd23, derivatives thereof, and their therapeutic uses

Publications (1)

Publication Number Publication Date
EA200001041A1 true EA200001041A1 (ru) 2001-06-25

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001041A EA200001041A1 (ru) 1998-05-09 1999-05-07 Антитела к cd23, их производные и их терапевтическое применение

Country Status (25)

Country Link
US (1) US7008623B1 (ru)
EP (1) EP1076701A1 (ru)
JP (1) JP2002514421A (ru)
KR (1) KR20010043470A (ru)
CN (1) CN1308676A (ru)
AP (1) AP1547A (ru)
AU (1) AU763491B2 (ru)
BR (1) BR9910327A (ru)
CA (1) CA2328606A1 (ru)
EA (1) EA200001041A1 (ru)
EE (1) EE200000658A (ru)
GB (1) GB9809839D0 (ru)
HR (1) HRP20000762A2 (ru)
HU (1) HUP0102005A3 (ru)
ID (1) ID28088A (ru)
IL (1) IL139384A0 (ru)
IS (1) IS5696A (ru)
NO (1) NO20005632L (ru)
NZ (1) NZ507879A (ru)
PL (1) PL344019A1 (ru)
SK (1) SK16762000A3 (ru)
TR (1) TR200003281T2 (ru)
WO (1) WO1999058679A1 (ru)
YU (1) YU69000A (ru)
ZA (1) ZA200006312B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
AU1174702A (en) 2000-10-13 2002-04-22 Biogen Inc Humanized anti-lt-beta-r antibodies
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
WO2004002431A2 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoyin beta receptor antibodies
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
AU2003300896A1 (en) * 2003-12-10 2005-07-14 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
JP2007530588A (ja) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
WO2006039470A2 (en) * 2004-09-29 2006-04-13 Centocor, Inc. Anti- amyloid antibodies, compositions, methods and uses
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
DK1957106T4 (da) 2005-11-14 2019-10-28 Teva Pharmaceuticals Int Gmbh Antagonist-antistoffer, der er rettet mod calcitonin-gen-relateret peptid og fremgangsmåder til anvendelse af disse
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
US20090155255A1 (en) * 2007-09-27 2009-06-18 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
ES2614284T3 (es) 2007-11-30 2017-05-30 Glaxo Group Limited Construcciones de unión a antígenos
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
TW201012489A (en) 2008-05-06 2010-04-01 Glaxo Group Ltd Encapsulation of biologically active agents
JP2012518398A (ja) 2009-02-24 2012-08-16 グラクソ グループ リミテッド 抗原結合性構築物
EP2401296A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
CA2753332A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2010122090A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Fgfr1c antibody combinations
US8623366B2 (en) 2009-08-28 2014-01-07 Labrys Biologics, Inc. Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
SG10201500388PA (en) 2010-11-23 2015-03-30 Glaxo Group Ltd Antigen binding proteins to oncostatin m (osm)
MX2013005847A (es) 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
EP3415531B1 (en) 2011-05-27 2023-09-06 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
CN105209494B (zh) 2013-03-15 2019-04-09 葛兰素史克知识产权开发有限公司 抗lag-3结合蛋白
JP6440036B2 (ja) * 2013-07-10 2018-12-19 オンコノックス エーピーエス 抗β２−グリコプロテインＩ抗体及びその治療的用法
KR20220130822A (ko) 2014-03-21 2022-09-27 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3344654B1 (en) 2015-09-02 2020-10-21 Immutep S.A.S. Anti-lag-3 antibodies
US10479827B2 (en) * 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
EP3515937A1 (en) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Treating refractory migraine
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DK1266965T3 (da) * 1991-07-25 2006-09-25 Biogen Idec Inc Rekombinante antistoffer til human terapi
WO1996012741A1 (en) * 1994-10-25 1996-05-02 Glaxo Group Limited Binding agents to cd23
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
NO20005632L (no) 2001-01-08
PL344019A1 (en) 2001-09-24
HRP20000762A2 (en) 2001-06-30
IL139384A0 (en) 2001-11-25
SK16762000A3 (sk) 2001-07-10
CA2328606A1 (en) 1999-11-18
WO1999058679A1 (en) 1999-11-18
NO20005632D0 (no) 2000-11-08
EP1076701A1 (en) 2001-02-21
ZA200006312B (en) 2003-02-26
AP1547A (en) 2006-01-13
ID28088A (id) 2001-05-03
BR9910327A (pt) 2001-01-30
KR20010043470A (ko) 2001-05-25
AP2000001983A0 (en) 2000-12-31
CN1308676A (zh) 2001-08-15
NZ507879A (en) 2004-02-27
YU69000A (sh) 2003-08-29
HUP0102005A3 (en) 2003-10-28
GB9809839D0 (en) 1998-07-08
JP2002514421A (ja) 2002-05-21
EE200000658A (et) 2002-04-15
AU763491B2 (en) 2003-07-24
AU3836799A (en) 1999-11-29
TR200003281T2 (tr) 2001-03-21
HUP0102005A2 (hu) 2001-10-28
US7008623B1 (en) 2006-03-07
IS5696A (is) 2000-10-31

Similar Documents

Publication Publication Date Title
EA200001041A1 (ru) Антитела к cd23, их производные и их терапевтическое применение
ATE364699T1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
EA200200262A1 (ru) Пиперазиновые производные и их применение в качестве противовоспалительных агентов
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
EA199800119A1 (ru) Ингибиторы адгезии клеток
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
EA199900559A1 (ru) Замещенные, азотсодержащие гетероциклы в качестве ингибиторов протеинкиназы p38
EP1408986A4 (en) PROTEOMIMETIC COMPOUNDS AND CORRESPONDING METHODS
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
TR200401638T2 (tr) Bir reseptöre bağlanan peptidler ve bileşikler.
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA200400312A1 (ru) АНТАГОНИСТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFSF13b ЧЕЛОВЕКА
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BR0013231A (pt) Complexos citocina-anticorpo múltiplos
EA200300508A1 (ru) Противовоспалительные агенты
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA199800946A1 (ru) Концентрированный препарат антител
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
EA199900621A1 (ru) Лечение рассеянного склероза путем приема внутрь или ингаляции сополимера-1
ATE527358T1 (de) Ribosomen inaktivierendes protein vom typ-1
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado